预约演示

更新于：2025-05-07

MPXV A29L

更新于：2025-05-07

基本信息

别名-

简介-

关联

项与 MPXV A29L 相关的药物

mRNA-B-LNP(Chinese PLA Academy of Military Medical Sciences)

靶点

MPXV A29L x MPXV A35R x MPXV B6R x MPXV M1R

作用机制

MPXV A29L抑制剂 [+3]

在研机构

中国人民解放军军事医学科学院

原研机构

中国人民解放军军事医学科学院

在研适应症

病毒感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

MPXV-1103

靶点

MPXV A29L x MPXV A35R x MPXV B6R x MPXV M1R

作用机制

MPXV A29L抑制剂 [+4]

在研机构

中国科学技术大学

原研机构

中国科学技术大学

在研适应症

猴痘

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

mRNA-A-LNP(Chinese PLA Academy of Military Medical Sciences)

靶点

MPXV A29L x MPXV A35R x MPXV B6R x MPXV M1R

作用机制

MPXV A29L抑制剂 [+3]

在研机构

中国人民解放军军事医学科学院

原研机构

中国人民解放军军事医学科学院

在研适应症

病毒感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 MPXV A29L 相关的临床结果

登录后查看更多信息

100 项与 MPXV A29L 相关的转化医学

登录后查看更多信息

0 项与 MPXV A29L 相关的专利（医药）

登录后查看更多信息

项与 MPXV A29L 相关的文献（医药）

2025-12-31·Emerging Microbes & Infections

An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge

Article

作者: Li, Entao ; Zhou, Jinge ; Yang, Qiyuan ; Gong, Qizan ; Zhang, Jiachen ; Chiu, Sandra ; Wang, Yucai ; Guo, Xiaoping ; Chuai, Xia ; Xie, Wenyu

Assessing the long-term efficacy of MPXV vaccine candidates is crucial for the global response to the ongoing mpox epidemic. Built upon our previous study of the mpox quadrivalent mRNA vaccine, herein we reported that MPXV-1103 could elicit sustained humoral and cellular immunity in mice, including the induction of MPXV A35/B6/A29/M1-specific IgG antibodies, VACV neutralizing antibodies and activated cytotoxic CD8⁺T cells, which provides 100% protection against lethal VACV challenge even at 280 days after the first vaccination. Our results provide critical insights for orthopoxvirus vaccine development.

2025-06-01·Biosensors and Bioelectronics

Development of a single-tube RPA/CRISPR-cas12a detection platform for monkeypox virus

Article

作者: Choi, Jeong-Woo ; Guo, Jinhong ; Li, Chenzhong ; Yang, Yang ; Liu, Shan ; Luo, Hongzhi ; Li, Xue

Monkeypox is a zoonotic disease caused by the monkeypox virus (MPXV), with outbreaks primarily occurring in West and Central Africa. The recent global MPXV outbreak underscores the urgent need for effective detection methods. Currently, qPCR is considered the gold standard for MPXV detection; however, it requires specialized personnel and costly equipment. This study introduces a CRISPR-Cas12a-based detection system targeting the MPXV A27L gene, achieving a detection limit as low as 10 aM. This system exhibits high specificity, with no cross-reactivity with other orthopoxviruses, and delivers results in under 40 min. To support point-of-care testing (POCT), we developed a lateral flow assay (LFA) strip for easy result visualization. The detection system was validated using six different clinical sample types, revealing that herpes fluid and saliva are the most suitable sources. The findings of this study align with qPCR results. Additionally, we lyophilized the RPA and CRISPR reagents to improve transport, storage, and field deployment. In conclusion, this study presents a reliable molecular diagnostic approach for early MPXV detection and point-of-care testing, contributing to epidemic prevention and control.

2024-10-01·Antiviral Research

An mpox quadrivalent mRNA vaccine protects mice from lethal vaccinia virus challenge

Article

作者: Li, Entao ; Li, Zhihao ; Zhang, Jiachen ; Wang, Yucai ; Guo, Xiaoping ; Chen, Da ; Shen, Yanqiong ; Xie, Wenyu ; Hong, Dongxiang ; Chiu, Sandra ; Wang, Qianqian ; Wang, Chao ; Gong, Qizan

The outbreak of 2022 monkeypox virus (MPXV) infection in nonendemic regions is a global public health concern. A highly effective and safe MPXV vaccine that is available to the general public is urgently needed to control the mpox pandemic. Here, we developed a multivalent mRNA vaccine candidate, MPXV-1103, which expresses the full-length B6, A35, A29 and M1 proteins with three flexible linkers (G₄S₁)₃ in a single sequence. Compared with the monovalent MPXV mRNA vaccine candidates or the quadrivalent mRNA vaccine from mixtures of the four monovalent MPXV mRNA vaccines, MPXV-1103 elicits a robust humoral response and an MPXV-specific T-cell response and protects mice from lethal vaccinia virus (VACV) challenge, with no live virus detected in the nasal or lungs even at dosages as low as 1 μg. Furthermore, analysis of complete blood counts and photomicrographs of tissue from the main organs of mice vaccinated with MPXV-1103 at doses of 5 μg and 20 μg revealed that two doses of MPXV-1103 did not cause any observable pathological changes in the mice. Collectively, our results suggest that MPXV-1103, with features of high efficacy, safety and a simplified manufacturing process, is a promising vaccine candidate for defending against MPXV infection.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。